Savolitinib - AstraZeneca

Drug Profile

Savolitinib - AstraZeneca

Alternative Names: AZD-6094; HMP-504; HMPL-504; Volitinib

Latest Information Update: 30 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hutchison MediPharma
  • Developer AstraZeneca; Hutchison MediPharma; National Cancer Institute (USA); Samsung Medical Center
  • Class Antineoplastics; Imidazoles; Pyrazines; Pyrazoles; Pyridines; Small molecules; Triazines; Triazoles
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Renal cell carcinoma
  • Phase II Gastric cancer; Lung cancer; Non-small cell lung cancer; Prostate cancer
  • No development reported Solid tumours

Most Recent Events

  • 27 Jul 2018 Hutchison China MediTech plans clinical trials for EGFR TKI-refractory Non-small cell lung cancer (Second-line therapy or greater, Combination therapy, in combination with gefitinib or erlotinib) globally, in early 2019
  • 27 Jul 2018 Hutchison China MediTech plans clinical trials for Non-small cell lung cancer (Second-line therapy or greater, Combination therapy, in combination with osimertinib), globally, in late 2018
  • 25 Jul 2018 National Cancer Institute plans a phase I trial for CNS cancer (Refractory metastatic disease) in USA (NCT03598244)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top